Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xenical orlistat: Phase III data; marketed

In 373 high risk obese patients, Xenical gave significantly greater

Read the full 107 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE